Cargando…
Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
OBJECTIVE: Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have failed to demonstrat...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930654/ https://www.ncbi.nlm.nih.gov/pubmed/20835310 http://dx.doi.org/10.4103/1817-1737.65047 |